| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $24,814,454 | 1 | 7 |
Sells | $4,753,623 | 13 | 93 |
| Liu Brian Guan-Chyun | director | 1 | $24.81M | 0 | $0 | $24.81M |
| POST LEONARD E | director | 0 | $0 | 8 | $1.05M | $-1.05M |
| Mulay James | director | 0 | $0 | 5 | $3.7M | $-3.7M |
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with …
Over the last 12 months, insiders at CG Oncology Inc. have bought $24.81M and sold $4.75M worth of CG Oncology Inc. stock.
On average, over the past 5 years, insiders at CG Oncology Inc. have bought $27.47M and sold $15.1M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Liu Brian Guan-Chyun (director) — $24.81M.
The last purchase of 371,085 shares for transaction amount of $24.81M was made by Liu Brian Guan-Chyun (director) on 2026‑06‑25.
| 2026-10-15 | Sale | POST LEONARD E | director | 1,000 0.0011% | $62.06 | $62,065 | +0.61% | |
| 2026-09-15 | Sale | POST LEONARD E | director | 1,000 0.0011% | $72.98 | $72,980 | -12.03% | |
| 2026-08-14 | Sale | POST LEONARD E | director | 1,000 0.0011% | $74.54 | $74,540 | -5.76% | |
| 2026-07-15 | Sale | POST LEONARD E | director | 1,000 0.0011% | $71.17 | $71,170 | -1.66% | |
| 2026-07-10 | Sale | Mulay James | director | 24,165 0.0274% | $75.16 | $1.82M | -4.51% | |
| 2026-06-25 | Liu Brian Guan-Chyun | director | 371,085 0.3862% | $66.87 | $24.81M | -1.47% | ||
| 2026-06-24 | Sale | POST LEONARD E | director | 5,000 0.006% | $70.00 | $350,000 | +4.50% | |
| 2026-06-22 | Sale | POST LEONARD E | director | 5,000 0.0056% | $65.00 | $325,000 | +8.29% | |
| 2026-06-15 | Sale | Mulay James | director | 1,310 0.0015% | $60.12 | $78,757 | +19.72% | |
| 2026-06-04 | Sale | POST LEONARD E | director | 1,000 0.0011% | $54.50 | $54,500 | +26.39% | |
| 2026-04-17 | Sale | Mulay James | director | 15,600 0.0184% | $73.01 | $1.14M | -5.60% | |
| 2026-03-16 | Sale | Mulay James | director | 1,310 0.0015% | $63.50 | $83,185 | +4.28% | |
| 2026-01-09 | Sale | Mulay James | director | 11,145 0.0144% | $52.47 | $584,799 | +23.01% | |
| 2025-11-17 | Sale | POST LEONARD E | director | 1,000 0.0013% | $41.43 | $41,430 | +55.85% | |
| 2025-10-13 | Sale | POST LEONARD E | director | 1,000 0.0013% | $43.25 | $43,250 | +47.35% | |
| 2025-10-09 | Sale | Mulay James | director | 5,903 0.0077% | $43.99 | $259,673 | +42.38% | |
| 2025-09-30 | Sale | POST LEONARD E | director | 5,000 0.0065% | $40.09 | $200,450 | +53.65% | |
| 2025-09-29 | Sale | Mulay James | director | 12,755 0.0168% | $39.19 | $499,868 | +58.34% | |
| 2025-09-19 | Sale | Mulay James | director | 3,574 0.005% | $38.99 | $139,350 | +63.93% | |
| 2025-09-18 | Sale | Mulay James | director | 19,112 0.0252% | $39.01 | $745,559 | +55.67% |
| Liu Brian Guan-Chyun | director | 1886236 2.128% | $120.83M | 2 | 0 | +78.62% |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 10 percent owner | 400000 0.4513% | $25.62M | 1 | 0 | <0.0001% |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 119 | +70.41% | 14M | +18.36% |
| Decreased Positions | 70 | -41.42% | 9M | -12.03% |
| New Positions | 46 | New | 7M | New |
| Sold Out Positions | 21 | Sold Out | 3M | Sold Out |
| Total Postitions | 218 | +28.99% | 83M | +6.34% |
| Vanguard Group Inc | $274,865.00 | 8.12% | 6.58M | +670,770 | +11.36% | 2025-09-30 |
| Decheng Capital Llc | $266,272.00 | 7.87% | 6.37M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $230,379.00 | 6.81% | 5.51M | +4M | +190.31% | 2025-09-30 |
| Blackrock, Inc. | $191,670.00 | 5.66% | 4.59M | +130,091 | +2.92% | 2025-09-30 |
| Fmr Llc | $161,552.00 | 4.77% | 3.87M | +9,541 | +0.25% | 2025-09-30 |
| Tcg Crossover Management, Llc | $153,378.00 | 4.53% | 3.67M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $137,210.00 | 4.05% | 3.28M | 0 | 0% | 2025-09-30 |
| Foresite Capital Management Vi Llc | $92,835.00 | 2.74% | 2.22M | 0 | 0% | 2025-09-30 |
| Alliancebernstein L.P. | $89,352.00 | 2.64% | 2.14M | -26,095 | -1.21% | 2025-09-30 |
| Ubs Group Ag | $88,857.00 | 2.63% | 2.13M | -102,975 | -4.62% | 2025-09-30 |